Accelerated infliximab infusions in inflammatory bowel disease
Phase 1
- Conditions
- Inflammatory bowel diseasesTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Registration Number
- EUCTR2021-000570-28-FI
- Lead Sponsor
- Tampere University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
IBD-patients who have received infliximab infusion ten times without infusion reactions
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 130
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Less than 18 year old children and adolescents
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method